Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cocrystal Pharma, Inc. (COCP)
|
Add to portfolio |
|
|
|
| Price: |
$0.68
| | Metrics |
| OS: |
10.2
|
M
| |
|
|
| Market cap: |
$6.92
|
M
| |
|
|
|
Net cash:
|
$32.4
|
M
| |
$3.19
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.0 | 2.0 | 6.6 | 0.0 | 0.0 | 0.0 | 0.1 | 5.7 |
| Revenue growth | -100.0% | -69.3% | | | | -100.0% | -98.6% | 2884.4% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.7 |
| Gross profit | 0.0 | 2.0 | 6.6 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
| Gross margin | | 100.0% | 100.0% | | | | 100.0% | 0.2% |
| Selling, general and administrative | | | | | | | | |
| Research and development | 8.8 | 6.0 | 4.0 | 4.7 | 5.8 | 101.7 | 47.3 | 4.1 |
| General and administrative | 5.4 | 5.6 | 4.9 | 4.4 | 2.4 | 4.1 | 6.8 | 1.7 |
| EBIT | -14.2 | -9.6 | -2.3 | -9.1 | -8.4 | -105.8 | -53.9 | -6.4 |
| EBIT margin | | -476.0% | -35.1% | | | | -69164.1% | -111.4% |
| Pre-tax income | -14.2 | -9.6 | -48.2 | -62.6 | -7.5 | -104.3 | -65.4 | -0.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | -13.6 | -6.9 | -29.4 | -15.2 | -0.1 |
| Tax rate | 0.0% | 0.0% | 0.0% | 21.7% | 91.8% | 28.2% | 23.3% | 34.4% |
| Net income | -14.2 | -9.6 | -48.2 | -49.0 | -0.6 | -74.9 | -50.1 | -0.1 |
| Net margin | | -479.0% | -733.8% | | | | -64259.0% | -1.7% |
| |
| Diluted EPS | ($0.16) | ($0.17) | ($1.51) | ($1.75) | ($0.03) | ($3.18) | ($2.39) | $0.00 |
| Shares outstanding (diluted) | 88.4 | 55.2 | 31.9 | 28.0 | 24.1 | 23.5 | 21.0 | 327.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|